Wikipedia

User:Mr. Ibrahem/Tenofovir alafenamide

< User:Mr. Ibrahem
Mr. Ibrahem/Tenofovir alafenamide
Clinical data
Pronunciation/ˌtəˈnoʊfəvɪər ˌæləˈfɛnəmaɪd/
Trade namesVemlidy
Genvoya (with elvitegravir, cobicistat and emtricitabine)
Odefsey (with emtricitabine and rilpivirine)
Descovy (with emtricitabine)
Symtuza (with darunavir, cobicistat, and emtricitabine)
Other namesGS-7340
AHFS/Drugs.comMonograph
License data
Pregnancy
category
Routes of
administration		By mouth (tablets)
Drug classReverse transcriptase inhibitor[2]
Legal status
Legal status
Pharmacokinetic data
Protein binding~80%[4]
Elimination half-life0.51 hour
ExcretionFeces (31.7%), urine (<1%)
Identifiers
  • Isopropyl (2S)-2-[[[(1R)-2-(6-aminopurin-9-yl)-1-methyl-ethoxy]methyl-phenoxy-phosphoryl]amino]propanoate
Chemical and physical data
FormulaC21H29N6O5P
Molar mass476.474 g·mol−1
3D model (JSmol)
  • C[C@H](CN1C=NC2=C(N=CN=C21)N)OC[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC3=CC=CC=C3
  • InChI=1S/C21H29N6O5P/c1-14(2)31-21(28)16(4)26-33(29,32-17-8-6-5-7-9-17)13-30-15(3)10-27-12-25-18-19(22)23-11-24-20(18)27/h5-9,11-12,14-16H,10,13H2,1-4H3,(H,26,29)(H2,22,23,24)/t15-,16+,33+/m1/s1
  • Key:LDEKQSIMHVQZJK-CAQYMETFSA-N

Tenofovir alafenamide, sold under the brand name Vemlidy, is a medication for the treatment of chronic hepatitis B in those with compensated liver disease.[5] It is taken by mouth.[5] It can be used in people over the age of 11.[2] Hepatitis B may worsen after stopping the medication.[5]

Common side effects include headache, nausea, and tiredness.[2] Other side effects may include lactic acidosis.[5] It is not recommended in severe liver problems.[5] Tenofovir alafenamide is converted by the body to tenofovir, by which it works.[2] This than blocks reverse transcriptase which prevents the virus from multiplying.[2]

Tenofovir alafenamide was approved for use in the United States in 2016 and Europe in 2017.[5][2] In the United States it costs about 1,300 USD per month as of 2021.[6] In the United Kingdom this amount costs the NHS about £325 and in Canada it is about 600 CAD.[7][8]

References edit

  1. ^ a b "Tenofovir alafenamide (Vemlidy) Use During Pregnancy". Drugs.com. 26 December 2018. Archived from the original on 9 July 2021. Retrieved 18 April 2020.
  2. ^ a b c d e f g h i j "Vemlidy EPAR". European Medicines Agency (EMA). Archived from the original on 13 July 2021. Retrieved 26 January 2021.
  3. ^ "Vemlidy 25 mg film coated tablets - Summary of Product Characteristics (SmPC)". (emc). 8 September 2020. Archived from the original on 11 July 2021. Retrieved 12 November 2020.
  4. ^ a b "Vemlidy- tenofovir alafenamide tablet". DailyMed. 11 February 2020. Archived from the original on 9 July 2021. Retrieved 18 April 2020.
  5. ^ a b c d e f "Tenofovir Alafenamide Monograph for Professionals". Drugs.com. Archived from the original on 18 January 2021. Retrieved 26 September 2021.
  6. ^ "Vemlidy Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 28 January 2021. Retrieved 26 September 2021.
  7. ^ BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 659. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
  8. ^ "Pharmacoeconomic Review Report TENOFOVIR ALAFENAMIDE (VEMLIDY)" (PDF). Archived (PDF) from the original on 18 October 2018. Retrieved 26 September 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Tenofovir_alafenamide&oldid=1199456589"